

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**PODESTAMATTOON**

2. Address:

1001 G STREET, NW SUITE 900 EAST, WASHINGTON, DC 20001

3. Principal place of business (if different from line 2):

Country: City: State/Zip(or Country):

4. Contact Name: KIMBERLEY FRITTS

Telephone: 202-393-1010

E-mail (optional): fritts@podestamattoon.com

Senate ID #: 31680-2512

House ID #: 31110190

7. Client Name: ☐ Self

**NOVO NORDISK PHARMACEUTICALS, INC.**

### TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): ☒ **OR** Year End (July 1 - December 31): ☐

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

### INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

#### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 100,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): \_\_\_\_\_

#### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only  
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

(Continued from page 2.) HR 5631 FY 2007 Department of Defense Appropriations bill - House version of the bill - diabetes/obesity initiatives, blood clotting issues Tracking Funds for the National Institute on Diabetes and Digestive and Kidneys HR 5441 FY 2007 Homeland Security Appropriations bill, The House Passed version: Titles III, Section 532 I Customs Drug Importation provision, The Senate Passed version: Customs Drug Importation provision HR 5647 FY 2007 Labor, Health and Human Services, and Education and Related Agencies Appropriations bill The House Committee Reported bill (Title II): NIDDK, drug pricing, drug safety HR 5672 - FY 2007 Science, State, Justice and Commerce Appropriations bill or Commerce, State and Justice Appropriations bill ; Patents/PTO HR 4939 Emergency Supplemental Appropriations for FY 2006 - Look for drug importation, drug pricing and drug safety provision, S Con Res. 83 - Senate Budget Resolution H Con Res. 376 - House Budget Resolution

17. House(s) of Congress and Federal agencies contacted:

Department of Health and Human Services

House of Representatives

National Institutes of Health

Senate Department of Health and Human Services

of Representatives

Health

House  
National Institutes of  
Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAKER, TEAL

Covered Official Position (if applicable):

Name: COHEN, SHARON

Covered Official Position (if applicable):

Name: COHEN, SHARON

Covered Official Position (if applicable):

Name: GERARD, RANDALL

Covered Official Position (if applicable):

Name: GERARD, RANDALL

Covered Official Position (if applicable):

Name: GERARD, RANDALL

Covered Official Position (if applicable):

Name: HASTERT, JOSH

Covered Official Position (if applicable):

Name: HASTERT, JOSHUA

Covered Official Position (if applicable):

Name: MATTOON, DAN

Covered Official Position (if applicable):

Name: MATTOON, DAN

Covered Official Position (if applicable):

Name: MORRA, ELIZABETH

Covered Official Position (if applicable):

Name: MORRA, ELIZABETH

Covered Official Position (if applicable):

Name: NICHOLS, SETH

Covered Official Position (if applicable):

Name: NICHOLS, SETH

Covered Official Position (if applicable):

Name: PODESTA, ANTHONY

Covered Official Position (if applicable):

Name: PODESTA, ANTHONY

Covered Official Position (if applicable):

Name: SICILIANO, JEN

Covered Official Position (if applicable):

Name: SICILIANO, JEN

Covered Official Position (if applicable):

Registrant Name: PODESTAMATTOON Client Name: NOVO NORDISK PHARMACEUTICALS, INC.

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

HR. 5384 - FY 2007 Agriculture, Rural Development, Food and Drug Administration Appropriations bill The House version of the Title VI; Section 742: ~~Conflict of Interest~~ Section 749 ~~Drug Importation~~ Section 751 ~~Drug safety~~ ~~Critical Path~~ ~~Drug safety~~ The Senate version of the bill: Title VI; Section 742 ~~FDA conflict on interest~~ language ~~Authorized Generics~~ ~~Citizen's Petition~~ and FTC ~~Personalized Medicine~~ ~~Critical Path, follow-on biologics~~ (cont. pg. 8 )HR 5441 ~~FY 2007 Homeland Security Appropriations bill~~ The House Passed version: Titles III, Section 532 ~~Customs Drug Importation provision~~ The Senate Passed version: Customs Drug Importation provision HR 5647 ~~FY 2007 Labor, Health and Human Services, and Education and Related Agencies Appropriations bill~~ The House Committee Reported bill (Title II): NIDDK, ~~Drug pricing, drug safety~~ HR 5672 - FY 2007 Science, State, Justice and Commerce Appropriations bill or Commerce, State and Justice Appropriations bill ; Patents/PTO HR 4939 Emergency Supplemental Appropriations for FY 2006 - Look for drug importation, drug pricing and drug safety provision, S Con Res. 83 - Senate Budget Resolution H Con Res. 376 - House Budget Resolution

17. House(s) of Congress and Federal agencies contacted:

Department of Health and Human Services

House of Representatives

National Institutes of Health

SenateDepartment of Health and Human Services

of Representatives

Health

House  
National Institutes of  
Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAKER, TEAL

Covered Official Position (if applicable):

Name: COHEN, SHARON

Covered Official Position (if applicable):

Name: COHEN, SHARON

Covered Official Position (if applicable):

Name: GERARD, RANDALL

Covered Official Position (if applicable):

Name: GERARD, RANDALL

Covered Official Position (if applicable):

Name: GERARD, RANDALL

Covered Official Position (if applicable):

Name: HASTERT, JOSH

Covered Official Position (if applicable):

Name: HASTERT, JOSHUA

Covered Official Position (if applicable):

Name: MATTOON, DAN

Covered Official Position (if applicable):

Name: MATTOON, DAN

Covered Official Position (if applicable):

Name: MORRA, ELIZABETH

Covered Official Position (if applicable):

Name: MORRA, ELIZABETH

Covered Official Position (if applicable):

Name: NICHOLS, SETH

Covered Official Position (if applicable):

Name: NICHOLS, SETH

Covered Official Position (if applicable):

Name: PODESTA, ANTHONY

Covered Official Position (if applicable):

Name: PODESTA, ANTHONY

Covered Official Position (if applicable):

Name: SICILIANO, JEN

Covered Official Position (if applicable):

Name: SICILIANO, JEN

Registrant Name: PODESTAMATTOON Client Name: NOVO NORDISK PHARMACEUTICALS, INC.

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R.2795, Patent Act of 2005 Patent Reform

17. House(s) of Congress and Federal agencies contacted:

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON

Covered Official Position (if applicable):

Name: NICHOLS, SETH

Covered Official Position (if applicable):

Name: PODESTA, ANTHONY

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.R.3010, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006  
Diabetes Research Issues

17. House(s) of Congress and Federal agencies contacted:  
Department of Health and Human Services  
House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON  
Covered Official Position (if applicable):  
Name: MORRA, ELIZABETH  
Covered Official Position (if applicable):  
Name: NICHOLS, SETH  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

H.R.3010, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006  
Diabetes Research Issues

17. House(s) of Congress and Federal agencies contacted:

Department of Health and Human Services

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON

Covered Official Position (if applicable):

Name: MORRA, ELIZABETH

Covered Official Position (if applicable):

Name: NICHOLS, SETH

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H.R.4241, Deficit Reduction Act of 2005 S.1932, Deficit Reduction Omnibus Reconciliation Act of 2005 Medicare drug coverage implementation issues 340B 2007 HOPPS reimbursement Diabetes screening benefit

17. House(s) of Congress and Federal agencies contacted:

Center for Medicare and Medicaid Services  
Department of Health and Human Services  
Executive Office of the President  
House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON

Covered Official Position (if applicable):

Name: HASTERT, JOSH

Covered Official Position (if applicable):

Name: NICHOLS, SETH

Covered Official Position (if applicable):

Name: PODESTA, ANTHONY

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

H.R.700, Pharmaceutical Market Access and Drug Safety Act of 2005 S.109, Pharmaceutical Market Access Act of 2005 S.334, Pharmaceutical Market Access and Drug Safety Act of 2005 S.930, Food and Drug Administration Safety Act of 2005 Drug safety and importation issues, Clinical trials Generics Biologics (cont. on page 10)

17. House(s) of Congress and Federal agencies contacted:

Department of Health and Human Services  
Food and Drug Administration  
House of Representatives  
Senate  
Department of Health and Human Services  
Food and Drug Administration  
House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON  
Covered Official Position (if applicable):  
Name: COHEN, SHARON  
Covered Official Position (if applicable):  
Name: GERARD, RANDALL  
Covered Official Position (if applicable):  
Name: GERARD, RANDALL  
Covered Official Position (if applicable):  
Name: HASTERT, JOSHUA  
Covered Official Position (if applicable):  
Name: HASTERT, JOSHUA  
Covered Official Position (if applicable):  
Name: NICHOLS, SETH  
Covered Official Position (if applicable):  
Name: NICHOLS, SETH  
Covered Official Position (if applicable):  
Name: PODESTA, ANTHONY  
Covered Official Position (if applicable):  
Name: PODESTA, ANTHONY  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

(Cont. from pg. 7) H.R. 328 - Pharmaceutical Market Access Act of 2005 H.R. 2090 - Food and Drug Administration Improvement Act of 2005 S. 2766 - National Defense Authorization Act for Fiscal Year 2007; Drug pricing

17. House(s) of Congress and Federal agencies contacted:

Department of Health and Human Services  
Food and Drug Administration  
House of Representatives  
Senate  
Department of Health and Human Services  
Food and Drug Administration  
House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON  
Covered Official Position (if applicable):  
Name: COHEN, SHARON  
Covered Official Position (if applicable):  
Name: GERARD, RANDALL  
Covered Official Position (if applicable):  
Name: GERARD, RANDALL  
Covered Official Position (if applicable):  
Name: HASTERT, JOSHUA  
Covered Official Position (if applicable):  
Name: HASTERT, JOSHUA  
Covered Official Position (if applicable):  
Name: NICHOLS, SETH  
Covered Official Position (if applicable):  
Name: NICHOLS, SETH  
Covered Official Position (if applicable):  
Name: PODESTA, ANTHONY  
Covered Official Position (if applicable):  
Name: PODESTA, ANTHONY  
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 10, 2006

Printed Name and Title: Kimberley Fritts - Managing Partner -